期刊
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
卷 38, 期 1, 页码 44-51出版社
WILEY
DOI: 10.1111/apt.12335
关键词
-
资金
- Pfizer
- Novartis
- Warner Chilcott
- Roche
- National Institute for Social Care and Health Research (NISCHR)
Background Symptoms compatible with irritable bowel syndrome (IBS) are frequently present in patients with inflammatory bowel disease (IBD); however, the cause of this phenomenon is unclear. Aim To determine the different contributions of true IBS' and sub-clinical inflammation in producing IBS-type symptoms in IBD patients, and to ascertain the impact these symptoms have on the clinical assessment of IBD activity. Methods In this cross-sectional study, 169 IBD patients completed questionnaires to assess disease activity, presence of IBS-type symptoms, and levels of anxiety and depression. Stool samples were collected for analysis of faecal calprotectin (FC). Results IBS-type symptoms were significantly more common in female patients (OR=4.64, 1.55-13.88) and were associated with higher levels of anxiety (OR=1.11, 1.01-1.21). There was no statistical difference between the FC levels of patients in clinical remission with IBS-type symptoms compared with those without (median values=111g/g vs. 45.5g/g respectively, P=0.171). The prevalence of IBS-type symptoms in patients with a normal FC level was 31%. Conclusions A substantial number of IBD patients with normal faecal calprotectin level experience IBS-type symptoms. These patients exhibit similar features to people diagnosed with IBS in the general community, suggesting that the conditions are not mutually exclusive and may coexist in a considerable number of IBD patients. A systematic diagnostic approach is required to assess IBD patients with IBS-type symptoms as sub-clinical inflammation may play a role in a proportion of cases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据